Baird raised the firm’s price target on DexCom (DXCM) to $87 from $82 and keeps an Outperform rating on the shares. The firm updated its model following Q4 results where there wer no major surprises but several incremental positives.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- DexCom price target raised to $90 from $78 at Mizuho
- Dexcom: Solid Q4 Execution, Durable Growth Drivers, and Innovation Pipeline Underpin Buy Rating and $85 Target
- DexCom price target lowered to $95 from $99 at Canaccord
- DexCom price target raised to $72 from $71 at Barclays
- Dexcom: Sustained Revenue Outperformance and Margin Expansion Underpin Buy Rating